<生产厂家价格>

(S)-(-)-舒必利

(S)-(-)-舒必利用途

Levosulpiride (RV-12309) 是Sulpiride的(S)对映体, 是多巴胺D2受体拮抗剂。

(S)-(-)-舒必利名称

[ CAS 号 ]:
23672-07-3

[ 中文名 ]:
左舒必利

[ 英文名 ]:
Levosulpiride

[中文别名 ]:

[英文别名 ]:

S-(-)-Sulpiride
(S)-(-)-Sulpiride
Levosulpiride
T5NTJ A2 B1MVR BO1 ESZW &&S Form
Sulpiride [L-(-)]
MFCD00055220
Levobren

(S)-(-)-舒必利生物活性

[ 描述 ]:

Levosulpiride (RV-12309) 是Sulpiride的(S)对映体, 是多巴胺D2受体拮抗剂。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 多巴胺受体

信号通路 >> 神经信号通路 >> 多巴胺受体

研究领域 >> 神经疾病

[相关活性小分子]

(S)-(-)-舒必利物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 熔点 ]:
183-186 °C(lit.)

[ 分子式 ]:
C₁₅H₂₃N₃O₄S

[ 分子量 ]:
341.426

[ 精确质量 ]:
341.140930

[ PSA ]:
110.11000

[ LogP ]:
0.45

[ 折射率 ]:
1.552

[ 储存条件 ]:
2-8°C

(S)-(-)-舒必利MSDS

详细MSDS(安全技术说明书)

(S)-(-)-舒必利毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: BZ3400100

CHEMICAL NAME :: o-Anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-, (S)-(-)-

CAS REGISTRY NUMBER :: 23672-07-3

LAST UPDATED :: 199109

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C15-H23-N3-O4-S

MOLECULAR WEIGHT :: 341.47

WISWESSER LINE NOTATION :: T5NTJ A2 B1MVR BO1 DSZW

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2600 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 270 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 53 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2450 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 170 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 17,437,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >1500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 42 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987

(S)-(-)-舒必利安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
BZ3400100

(S)-(-)-舒必利制备

方法1：其制备和舒必利相同，只不过是2-氨甲基-1-乙基吡咯烷在和2-甲氧基-5-氨基磺酰苯甲酸甲酯反应前，先进行化学拆分，得S型后再反应。室温下，把消旋的2-氨甲基-1-乙基吡咯烷滴加到D-(-)-酒石酸的水溶液中，搅拌。再加入无水乙醇，在冰箱中放置过夜。滤集固体，和甲醇一起回流，热滤，干燥得酒石酸盐，收率36.8%。该盐和氢氧化钠水溶液于室温下搅拌，氯仿萃取。萃取液干燥后浓缩，减压蒸馏，收集65℃/2.0kPa的馏分，得(S)-(-)-2氨甲基-1-乙基吡咯烷，收率43.5%。得到的S型的吡咯烷，和2-甲氧基-5-氨基磺酰苯甲酸甲酯在乙二醇中，于120℃搅拌。冷至5℃过滤，得到的粗品用95%乙醇重结晶，得左舒必利，收率72.6%，熔点184～186℃，[α]_D²³-66.4°(C=0.5，二甲基甲酰胺)。
方法2：以左旋脯氨酸为原料，经酰化、还原、氯化、氨化和缩合五步反应得左舒必利。L-脯氨酸溶于水，滴加乙酐。在90℃搅拌，冷却，抽滤，少量冰水洗。滤液浓缩至1/2体积，加异丙醇。滤集结晶，干燥得酰化产物L-N-乙酰脯氨酸，收率90%。将其溶于四氢呋喃中，缓慢滴入氢化铝锂的四氢呋喃溶液，回流。在冰浴冷却下，先滴加四氢呋喃和水的混合液，再滴加20%氢氧化钠溶液。过滤，滤液干燥，再过滤。蒸出溶剂，收集76～78℃/2.0kPa馏分，得化合物(I)，收率79.8%。将化合物(I)溶于二氯甲烷，在冰浴冷却下，缓慢滴加氯化亚砜，室温搅拌后再回流。浓缩至于，加入无水乙醇一氨溶液，20℃搅拌。蒸去溶剂，加入水，50％氢氧化钠调至Ph值10。乙醚提取，干燥，过滤，蒸去溶剂，收集70～74℃/1.6kPa馏分，得化合物(Ⅱ)，收率65%。化合物(Ⅱ)和化合物(Ⅲ)溶于乙二醇，在80～85℃搅拌，并蒸出生成的甲醇。冷却，过滤，乙醇重结晶，得左舒必利，收率。75%，熔点186～187℃，[α]_D²⁰-68.79°(C=1%，二甲基甲酰胺)。

(S)-(-)-舒必利文献

Chemical genetics reveals a complex functional ground state of neural stem cells.

Nat. Chem. Biol. 3(5) , 268-273, (2007)

The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain canc...

The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry.

Drug Test. Anal. 7 , 502-11, (2015)

Therapeutic drug monitoring of antipsychotics is important in optimizing individual therapy. In psychiatric populations, classical venous blood sampling is experienced as frightening. Interest in alte...

5-HT2A receptor activation is necessary for CO2-induced arousal.

J. Neurophysiol. 114 , 233-43, (2015)

Hypercapnia-induced arousal from sleep is an important protective mechanism pertinent to a number of diseases. Most notably among these are the sudden infant death syndrome, obstructive sleep apnea an...

更多文献